Table 2

Univariate and multivariate analyses of genotype versus development of osteonecrosis

Gene, rs no/genotypePatients successfully genotyped, %Osteonecrosis, no.
Univariate analysis
Multivariate analysis
YesNoOdds ratio95% CIPOdds ratio95% CIP
Thymidylate synthetase (TYMS) enhancer repeat 86   1.40 0.72-2.74 .326 1.42 0.72-2.80 .319 
    2R/2R  16 80       
    All others  27 189       
Vitamin D receptor start codon Fok1 (VDR) rs2228570 84   1.70 0.82-3.53 .153 1.91 0.90-4.03 .091 
    TT/CT  32 164       
    CC  11 96       
Osteocalcin (BGLAP) rs1800247 66   0.87 0.28-2.73 .817 0.88 0.27-2.84 .824 
    TT/CT  32 183       
    CC  4 20       
Estrogen receptor alpha (ESR1) rs2234693 61   0.68 0.32-1.46 .328 0.64 0.29-1.42 .276 
    CC/CT  13 95       
    TT  19 95       
Low-density lipoprotein receptor-related protein (LRP5) rs2306862 70   0.72 0.36-1.41 .336 0.68 0.34-1.37 .281 
    TT/CT  18 113       
    CC  22 99       
5,10-Methylenetetrahydrofolate reductase (MTHFR) rs1801133 71   1.30 0.68-2.51 .432 1.22 0.62-2.41 .563 
    TT/CT  22 95       
    CC  21 118       
Plasminogen activator inhibitor-1 (PAI-1) rs6092 81   2.79 1.45-5.34 .002 2.89 1.48-5.62 .002 
    AA/GA  21 57       
    GG  25 189       
P-glycoprotein (ABCB1) rs1045642 77   1.35 0.65-2.82 .422 1.52 0.71-3.23 .278 
    TT/CT  33 162       
    CC  11 73       
Parathyroid hormone (PTH) rs6254 76   0.75 0.39-1.44 .393 0.75 0.38-1.47 .404 
    AA/GT  19 115       
    GG  25 114       
Parathyroid hormone receptor (PTHR) rs1138518 69   0.69 0.34-1.42 .313 0.72 0.34-1.50 .377 
    CC/TC  16 117       
    TT  19 96       
Tartrate-resistant acid phosphatase (ACP5) rs2229531 73   0.81 0.30-2.22 .683 0.84 0.30-2.36 .733 
    AA/GT  5 31       
    GG  38 191       
Tartrate-resistant acid phosphatase (ACP5) rs2305799 77   0.77 0.34-1.75 .527 .82 0.35-1.92 .650 
    TT/CT  8 54       
    CC  35 181       
Gene, rs no/genotypePatients successfully genotyped, %Osteonecrosis, no.
Univariate analysis
Multivariate analysis
YesNoOdds ratio95% CIPOdds ratio95% CIP
Thymidylate synthetase (TYMS) enhancer repeat 86   1.40 0.72-2.74 .326 1.42 0.72-2.80 .319 
    2R/2R  16 80       
    All others  27 189       
Vitamin D receptor start codon Fok1 (VDR) rs2228570 84   1.70 0.82-3.53 .153 1.91 0.90-4.03 .091 
    TT/CT  32 164       
    CC  11 96       
Osteocalcin (BGLAP) rs1800247 66   0.87 0.28-2.73 .817 0.88 0.27-2.84 .824 
    TT/CT  32 183       
    CC  4 20       
Estrogen receptor alpha (ESR1) rs2234693 61   0.68 0.32-1.46 .328 0.64 0.29-1.42 .276 
    CC/CT  13 95       
    TT  19 95       
Low-density lipoprotein receptor-related protein (LRP5) rs2306862 70   0.72 0.36-1.41 .336 0.68 0.34-1.37 .281 
    TT/CT  18 113       
    CC  22 99       
5,10-Methylenetetrahydrofolate reductase (MTHFR) rs1801133 71   1.30 0.68-2.51 .432 1.22 0.62-2.41 .563 
    TT/CT  22 95       
    CC  21 118       
Plasminogen activator inhibitor-1 (PAI-1) rs6092 81   2.79 1.45-5.34 .002 2.89 1.48-5.62 .002 
    AA/GA  21 57       
    GG  25 189       
P-glycoprotein (ABCB1) rs1045642 77   1.35 0.65-2.82 .422 1.52 0.71-3.23 .278 
    TT/CT  33 162       
    CC  11 73       
Parathyroid hormone (PTH) rs6254 76   0.75 0.39-1.44 .393 0.75 0.38-1.47 .404 
    AA/GT  19 115       
    GG  25 114       
Parathyroid hormone receptor (PTHR) rs1138518 69   0.69 0.34-1.42 .313 0.72 0.34-1.50 .377 
    CC/TC  16 117       
    TT  19 96       
Tartrate-resistant acid phosphatase (ACP5) rs2229531 73   0.81 0.30-2.22 .683 0.84 0.30-2.36 .733 
    AA/GT  5 31       
    GG  38 191       
Tartrate-resistant acid phosphatase (ACP5) rs2305799 77   0.77 0.34-1.75 .527 .82 0.35-1.92 .650 
    TT/CT  8 54       
    CC  35 181       

CI indicates confidence interval.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal